Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A multivariate analysis for predicting cisplatin-induced delayed emesis.

X Pivot1, N Marghali, M C Etienne

  • 1Centre Antoine Lacassagne, Oncopharmacology Unit, 06189 Nice, France.

Oncology Reports
|April 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation-associated angiosarcoma of the breast: consider chemotherapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Prognostic Values of Pre- and Post-Therapeutic FDG-PET in Anal Canal Cancer: Analysis of a Prospective Study.

Clinical colorectal cancer·2025
Same author

Chicken liver morphology as affected by feed withdrawal time and dietary aflatoxins.

British poultry science·2022
Same author

%TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology.

Computer methods and programs in biomedicine·2021
Same author

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.

PloS one·2020
Same author

Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same journal

Identification of RRM2 as a key regulator of malignant epithelial cells in gastric cancer through single‑cell transcriptomics.

Oncology reports·2026
Same journal

Impact of WFDC2 on the biological functions of cervical cancer cells and the regulation of the ERK/NF‑κB signaling pathway.

Oncology reports·2026
Same journal

Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.

Oncology reports·2026
Same journal

Research advances on DKK1 in head and neck squamous cell carcinoma: Linking molecular mechanisms to clinical applications (Review).

Oncology reports·2026
Same journal

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

Oncology reports·2026
Same journal

A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer.

Oncology reports·2026
See all related articles

Early identification of patients at risk for cisplatin (CP)-related delayed emesis is possible. Elevated ultrafilterable platinum and low magnesium levels predict delayed vomiting, enabling targeted interventions.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Chemistry

Background:

  • Cisplatin (CP) chemotherapy can cause delayed emesis, impacting patient quality of life.
  • Early identification of patients at risk for delayed emesis is crucial for effective management.

Purpose of the Study:

  • To identify early predictors of delayed emesis in patients receiving cisplatin-based chemotherapy.
  • To establish risk thresholds for key biomarkers associated with delayed vomiting.

Main Methods:

  • Prospective study of 110 patients undergoing CP-based chemotherapy.
  • Analysis of demographic, clinical, biological, and pharmacokinetic data.
  • Measurement of ultrafilterable platinum and plasma magnesium concentrations at specific time points.

Related Experiment Videos

Main Results:

  • Delayed emesis occurred in 36.4% of analyzed cycles.
  • Elevated ultrafilterable platinum and low plasma magnesium were significantly associated with delayed emesis.
  • Risk thresholds were identified: UF platinum >60 ng/ml and magnesemia <58 mmol/l.

Conclusions:

  • Ultrafilterable platinum and plasma magnesium levels can predict cisplatin-induced delayed emesis.
  • Low magnesium was the sole significant predictor in a subgroup analysis.
  • Identifying at-risk patients allows for targeted antiemetic strategies.